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Mammary Tumors Induce Central 
Pro-inflammatory Cytokine 
Expression, but Not Behavioral 
Deficits in Balb/C Mice
William H. Walker II1,2,3, Jeremy C. Borniger1,2,3, Surbhi1,2,3, Abigail A. Zalenski1,2,3,  
Stevie L. Muscarella1,2,3, Julie A. Fitzgerald1,2,3, Ning Zhang1,2,3, Monica M. Gaudier-Diaz1,2,3 & 
A. Courtney DeVries1,2,3
Breast cancer survivors are more likely to develop mood disorders and cognitive deficits than women in 
the general population. Previous studies suggest that peripheral tumors elicit central pro-inflammatory 
cytokine production, in turn leading to depression and cognitive deficits. In the current study, two cohorts 
of female Balb/C mice received bilateral orthotopic injections of syngeneic 67NR, 4T07, or 4T1cells 
(1 × 105 cells per injection) to induce mammary tumors. Approximately three weeks later, learned fear 
(via fear conditioning) or depressive-like behavior (via tail suspension and forced swim test) was assessed. 
Proinflammatory cytokine levels were increased in the serum (IL-1β, TNFα, IFNγ) and livers (IL-1β, IL-6, 
TNFα) of mice with 4T07 or 4T1 tumors compared to 67NR tumors and the vehicle control. IL-1β was 
increased in both the hippocampus and cortex of mice injected with 4T07 or 4T1 cell lines relative to the 
other treatment groups. However, mammary tumors had no effect on hippocampal doublecortin + and 
did not alter depressive-like behavior or learned fear. These data demonstrate that similarly sized tumors 
can produce differential immune responses and that tumor-induced central pro-inflammatory cytokine 
production can exist in the absence of depressive-like behavior or cognitive deficits.
Breast cancer is one of the most common types of cancer among women in the United States. According to the 
National Cancer Institute and American Cancer Society, there are currently more than 3 million breast cancer 
survivors in the United States, and approximately 252,000 women will be diagnosed with breast cancer in 2017. 
Unfortunately, these women are 25–30% more likely to be diagnosed with a mood disorder relative to the general 
population; indeed, some estimates suggesting that as many as 50% of breast cancer survivors could develop a 
comorbid mood disorder1, 2. Although many breast cancer survivors will go on to develop a comorbid mood disor-
der, the most common of these are depression and anxiety, symptoms also may manifest as cognitive disturbances1. 
These findings are of major concern, because comorbid depression, along with cognitive disturbances, are asso-
ciated with reduced quality of life, reduced treatment compliance, increased cancer progression, and reduced 
survival rates3–9.
The cause of cancer-related affective disorders and cognitive deficits has not been conclusively established. 
However, the inflammatory and neurodegenerative hypothesis of depression has been proposed to explain these 
deficits10. Several studies indicate that peripheral tumors, induced via carcinogens or metastatic cell lines, result 
in central pro-inflammatory cytokine production and the development of depressive-like behavior11–14. Along 
with activating the peripheral immune system, mammary tumor cells can secrete proinflammatory cytokines 
including interleukin 6 (IL-6) and interleukin 1 beta (IL-1β)11, 15; these signals are then likely transmitted to the 
brain via humoral or vagal signaling16–19. Within the brain, these proinflammatory cytokines are hypothesized 
to activate microglia, which then propagate this signal, in turn contributing to the induction of depressive-like 
behavior and cognitive deficits18.
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Whereas potential mechanisms underlying the transmission of peripheral cytokine signals to the brain are 
well understood, the mechanisms through which central pro-inflammatory cytokine production can induce 
depressive-like behavior and cognitive deficits remain speculative. There are proposals regarding how this phe-
nomenon occurs. Current hypotheses include (1) degradation of tryptophan along the kynurenine pathway 
through actions on indoleamine 2–3-dioxygenase (IDO), (2) decreased neurogenesis, or (3) increased neurode-
generation through actions on neurotrophins, particularly brain-derived neurotrophic factor (BDNF)10, 18.
Thus, affective deficits have been documented in tumor-bearing rodents, but whether these behavioral deficits 
are related to central pro-inflammatory cytokine production and altered neurogenesis remains to be determined. 
Thus, the current study sought to compare the effects of three types of orthotopic mammary tumors on peripheral 
and central inflammation, as well as hippocampal neurogenesis (DCX + cells), affective behaviors, and cognitive 
function. We generated tumors using multiple cell lines (67NR, 4T07, and 4T1) obtained from Barbara Ann 
Karmanos Cancer Institute (Detroit, MI); these cell lines are distinct isolated subpopulations from a single spon-
taneous Balb/cfC3H mammary tumor, and differ in their ability to induce secondary metastasis20.
Results
Cohort 1. Body Mass Changes and Tumor Cytokine Production are Cell Line Specific. Cachexia is a common 
side effect of late stage cancer. There was a significant effect of treatment on body mass (F3,50 = 3.92, p < 0.05) 
measured on the final day of the experiment; mice injected with 4T1 cells had reduced body mass compared to 
vehicles (Fig. 1A, p < 0.05, Tukey’s multiple comparisons). The experimental groups injected with either 67NR 
or 4T07 cells had mean body weights that were intermediate between the vehicle treated group and the 4TI 
treated group, but not significantly different from either (p > 0.05). To rule out a potential confound associated 
with tumor size, tumor masses were recorded but did not differ among groups (Fig. 1B, F2,38 = 2.04, p > 0.05). 
There were no group differences in tumor protein concentrations of IFN-γ, IL-2, IL-4, IL-5, IL-10, and IL-12p70 
(Fig. 1C, p > 0.05 data not shown). However, there was a significant effect of tumor cell type on IL-1β (Fig. 1C, 
H = 29.44, p < 0.0001), IL-6 (Fig. 1C, F2,37 = 13.68, p < 0.0001), TNFα (Fig. 1C, F2,38 = 26.73, p < 0.0001), and 
CXCL1 (Fig. 1C, H = 10.86, p < 0.005). Specifically, tumors generated with 4T07 or 4T1 cells had significantly 
greater IL-1β (p < 0.05, Dunn’s multiple comparisons) and IL-6 (p < 0.05, Dunn’s multiple comparisons) con-
centrations than tumors generated with 67NR cells. Tumors generated with 4T07 cells had significantly more 
TNFα (p < 0.05, Tukey’s multiple comparisons) than tumors generated with either 4T1 or 67NR cells. TNFα 
production also was significantly elevated in 4T1 tumors relative to 67NR tumors (p < 0.05, Tukey’s multiple 
comparisons). CXCL1 concentration was significantly elevated in 4T07 tumors when compared to 67NR tumors 
(p < 0.05, Dunn’s multiple comparisons), and 4T1 tumors had an intermediate concentration of CXCL1, with no 
significant differences relative to 67NR or 4T07 tumors (p > 0.05, Dunn’s multiple comparisons).
Mammary Tumors Alter Spleen Mass and Cytokine Production. There was a significant effect of treatment 
on spleen mass (Fig. 1D, H = 40.50, p < 0.001). Mice injected with either 4T07 or 4T1 cells displayed a signif-
icant increase in spleen mass when compared to either the vehicle or 67NR treated groups (p < 0.05 in all cases, 
Dunn’s multiple comparisons test). There was a concomitant effect of treatment on CD11b mRNA levels (Fig. 1E, 
H = 40.76, p < 0.001), with 4T07 or 4T1 treated groups exhibiting significantly greater CD11b mRNA expression 
in the spleen when compare to either the 67NR or vehicle treated groups (Fig. 1E, p < 0.05 in all cases, Dunn’s 
multiple comparisons). TNFα mRNA expression was reduced among all tumor bearing groups compared to 
vehicle treated animals (Fig. 1H, F3,50 = 13.32, p < 0.001, p < 0.05 in all cases, Tukey’s multiple comparisons). 
Spleen IL-10 mRNA expression also was reduced among 4T07 or 4T1 tumors when compared to either 67NR 
or vehicle treated groups (Fig. 1I, H = 29.54, p < 0.05 in all cases, Dunn’s multiple comparisons). However, there 
were no significant differences among groups in spleen mRNA levels of IL-1β (Fig. 1F, F3,51 = 1.185, p > 0.05) or 
IL-6 (Fig. 1G, H = 2.735, p > 0.05)
Mammary Tumors Increase Serum Cytokine Concentrations. There were significant effects of treatment on 
concentrations of IL-1β (Fig. 2A, H = 35.91,p < 0.0001), IL-6 (Fig. 2B, F3,50 = 19.90,p < 0.0001), TNFα (Fig. 2C, 
H = 40.65,p < 0.0001), IFNγ (Fig. 2E, H = 41.74,p < 0.0001), IL-2 (Fig. 2F, F3,49 = 8.266,p < 0.0001), IL-10 
(Fig. 2G, H = 40.03,p < 0.0001), IL-4 (Fig. 2H, H = 22.52,p < 0.0001), and IL-5 (Fig. 2I, H = 37.13,p < 0.0001), 
along with a decrease in CXCL1 (Fig. 2D, H = 43.75,p < 0.0001). IL-12p70 failed to reach a detectable range 
in the serum. Specifically, mice treated with either 4T07 or 4T1 cells had significantly higher concentrations of 
IL-1β, TNFα, IFNγ, IL-10, IL-4, and IL-5, along with a significant reduction in CXCL1, when compared to either 
the vehicle or 67NR treated group (Fig. 2A–I excl. B and F, p < 0.05 in all cases, Dunn’s multiple comparisons). 
Serum IL-6 and IL-2 was increased in mice receiving 4T1 cell injections when compared to either vehicle or 67NR 
treated mice (Fig. 2B and F, p < 0.05, Tukey’s multiple comparisons). 4T07 treated mice had significantly elevated 
serum IL-6 only when compared to vehicle mice and a significant increase in serum IL-2 only when compared 
to 67NR treated mice (2B and F, p < 0.05, Tukey’s multiple comparisons). At this time point (Day 20 post-tumor 
inoculation), the vehicle and 67NR groups did not differ significantly in any cytokine concentration. There were 
no correlations between tumor cytokine concentrations and serum cytokine concentrations for any cytokine 
measured (data not shown, p > 0.05 in all cases, Pearson’s correlation coefficient).
Mammary Tumors Increase Liver Inflammation. Mice with either 4T07 or 4T1 tumors had increased liver 
mRNA production of IL-1β (Fig. 3A, H = 34.10, p < 0.001), IL-6 (Fig. 3B, H = 29.12, p < 0.001), and TNFα 
(Fig. 3C, H = 35.31, p < 0.001) compared to either the vehicle or 67NR tumor-bearing mice (Fig. 3A–C, p < 0.05 
in all cases, Dunn’s multiple comparisons). However, no group differences in IFNγ mRNA were detected (Fig. 3D, 
F3,50 = 1.297, p > 0.05). Likewise, there were group differences in STAT3 (Fig. 3E, F3,49 = 4.261, p < 0.01) and 
Socs3 (Fig. 3F, H = 35.52, p < 0.001) expression; specifically, mice with 4T1 tumors had increased STAT3 mRNA 
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levels when compared to vehicle treated mice (Fig. 3E, p < 0.05, Tukey’s multiple comparisons), while mice with 
4T07 or 67NR tumors displayed an intermediate phenotype which was not significantly different from any other 
group (Fig. 3E, p > 0.05, Tukey’s multiple comparisons). Liver Socs3 mRNA expression was increased in both 
4T07 and 4T1 compared to the vehicle and 67NR treated mice (Fig. 3F and I, p < 0.05 in all cases, Dunn’s multiple 
comparisons).
Mammary Tumors Result in Central Pro-inflammatory Cytokine Production. Mice with 4T07 or 4T1 tum-
ors had significantly elevated cortical concentrations of IL-1β (Fig. 4A, H = 37.07, p < 0.0001) and CXCL1 
(Fig. 4D, H = 19.26, p < 0.001), along with increased hippocampal concentrations of IL-1β (Fig. 4E, F3,51 = 24.04, 
p < 0.0001) compared to either the vehicle or 67NRtumor groups (Fig. 4A,D,E, p < 0.05, Tukey’s multiple com-
parisons). These increases in IL-1β were further confirmed in both the hippocampus (data not shown, H = 34.29, 
p < 0.001) and cortex (data not shown, H = 34.84, p < 0.001) via qPCR, which showed elevations that were iden-
tical to the protein data. However no group differences existed in cortical IL-6 (Fig. 4B, F3,52 = 1.037, p > 0.005), 
TNFα (Fig. 4C, F3,36 = 3.964, p > 0.005), IFNу (data not shown, H = 5.565, p > 0.005), IL-4 (data not shown, 
F3,47 = 0.1261, p > 0.005), IL-5 (data not shown, F3,50 = 1.885, p > 0.005), IL-10 (data not shown, F3,48 = 0.042, 
p > 0.005), or hippocampal IL-6 (Fig. 4F, F3,52 = 1.727, p > 0.005), TNFα (Fig. 4G, F3,50 = 3.197, p > 0.005), 
CXCL1 (Fig. 4H, F3,51 = 2.673, p > 0.005), IFNγ (data not shown, F3,50 = 2.037, p > 0.005), IL-2 (data not shown, 
F3,51 = 1.212, p > 0.005), IL-4 (data not shown, F3,52 = 1.171, p > 0.005), IL-5 (data not shown, F3,52 = 2.111, 
p > 0.005), IL-10 (data not shown, F3,52 = 0.6636, p > 0.005), or IL-12p70 (data not shown, F3,46 = 0.4249, 
p > 0.005). Concentrations of two cytokines IL-2 and IL-12p70 failed to reach the detectable range in the cortex. 
Figure 1. The Effects of Mammary Tumors on Body Mass and the Peripheral Cytokine Response Are Cell 
Line Specific. (A) Change in body mass between date of tumor inoculation (DOI) and date of euthanasia 
(DOE) accounting for tumor mass (TTB) for vehicle and each cell line ((DOE-DOI)-TTB); only mice with 4T1 
tumors had significant body mass loss relative to the vehicle controls. (B) Total tumor burden in grams, and 
as a percentage of body mass, did not differ between cell lines. (C) Protein cytokine concentrations of IL-1β, 
IL-6, and TNF-α were elevated in 4T07 and 4T1 tumors relative to 67NR tumors. CXCL1 was elevated in 4T07 
tumors relative to 67NR and 4T1 tumors. (D) Spleen mass was elevated among mice with 4T07 and 4T1 tumors 
relative to 67NR tumors and vehicle treated mice. (E–I) Spleen mRNA expression expressed as fold change from 
vehicles. (E) Macrophage marker CD11b was elevated in 4T07 and 4T1 tumors relative to vehicles and 67NR 
tumors. (F and G) Spleen IL-1β and IL-6 mRNA did not differ between groups. (H) TNFα mRNA expression 
was significantly reduced in all cell lines relative to vehicles.(I) IL-10 expression was significantly reduced in 
4T07 and 4T1 tumors relative to 67NR tumors and vehicles. The measures and tissues were collected 20 days 
after tumor cell or vehicle inoculation (n = 12–15/group). The data are presented as mean + SEM. Graph bars 
that do not share a letter are statistically significant different at p < 0.05.
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Further, no significant differences existed in IDO1 (Fig. 4I, F3,48 = 0.3495, p > 0.05), IDO2 (Fig. 4J, F3,48 = 0.1111, 
p > 0.05) BDNF (Fig. 4K, F3,50 = 0.7519, p > 0.05), PSD-95 (Fig. 4L, F3,51 = 1.095, p > 0.05), or iNOS (data not 
shown, F3,47 = 1.827, p > 0.05) as measured by qPCR. Also, there was no significant correlation in 4T07 or 4T1 
treated mice between serum IL-1β or TNFα and IL-1β or TNFα concentrations in either the hippocampus or 
cortex (data not shown, p > 0.05, Pearson’s correlation coefficient).
Mammary Tumors Do Not Alter Locomotor Activity or Depressive-like Behavior. There were no group differences 
in total locomotor activity, anxiety-like behavior, or depressive-like behavior as measured by total beam breaks 
and central tendency during open field testing (Fig. 5A, F3,52 = 0.6453, p > 0.05; data not shown, F3,51 = 0.4920, 
p > 0.05), number of floating bouts, total time floating, and latency to float during the forced swim test (Fig. 5D, 
F3,49 = 0.0978, p > 0.05; Fig. 5C, F3,49 = 1.207, p > 0.05; data not shown, F3,51 = 0.7222, p > 0.05), and number 
of immobile bouts, time spent immobile, and latency to immobility during tail suspension (data not shown, 
F3,46 = 0.2459, p > 0.05; Fig. 5B, F3,46 = 0.222, p > 0.05; data not shown, H = 1.571, p > 0.05). To rule out a poten-
tial effect of timing of the behavioral tests, we tested a separate cohort of animals with the same treatment groups 
during the dark phase of the light-dark cycle. These mice also did not exhibit group differences in total locomotor 
activity or anxiety-like behavior as measured by total beam breaks and central tendency during open field test-
ing (data not shown, H = 7.503, p > 0.05; data not shown, F3,26 = 1.148, p > 0.05), or depressive-like behavior as 
measured by number of floating bouts (data not shown, F3,28 = 0.5950, p > 0.05), and total time floating during 
the forced swim test (data not shown, F3,27 = 0.4108, p > 0.05).
Cohort 2. Mammary Tumors Induce Central Pro-Inflammatory Cytokine Production but Have No Effect on 
Learned Fear or DCX + Cell Number. As reported in cohort one, 4T1 mammary tumors resulted in a significant 
reduction in body mass (Fig. 6A, F2,41 = 3.377, p < 0.05), increase in spleen mass (Fig. 6C, H = 31.48, p < 0.001), 
and increases in hippocampal cytokine concentrations of IL-1β (Fig. 6D, H = 24.59, p < 0.0001) compared to 
the non-tumor bearing vehicle-treated controls. In contrast to cohort one, total tumor mass was greater among 
Figure 2. 4T07 and 4T1 Tumors Increase Serum Cytokine Concentrations. (A–I) Serum protein cytokine 
concentrations of IL-1β, IL-6, TNFα, CXCL1, IFNγ, IL-2, IL-10, IL-4, and IL-5 expressed in both vehicle 
and treatment groups. (A) Serum IL-1β was significantly increased in 4T07 and 4T1 tumors relative to 67NR 
tumors and vehicles. (B). Serum IL-6 was increased in 4T07 and 4T1 tumors relative to vehicles. (C) TNFα 
concentrations were significantly increased in 4T07 and 4T1 tumors relative to 67NR tumors and vehicles. (D) 
Serum CXCL1 was significantly reduced in 4T07 and 4T1 tumors relative to 67NR tumors and vehicles. (E) 
IFNγ concentrations were significantly increased in 4T07 and 4T1 tumors relative to 67NR tumors and vehicles. 
(F) Serum IL-2 was increased in 4T07 and 4T1 tumors relative to 67NR tumors. (G–I) Serum IL-10, IL-4, and 
IL-5 was significantly increased in 4T07 and 4T1 tumors relative to 67NR tumors and vehicles. The measures 
and tissues were collected 20 days after tumor cell or vehicle inoculation (n = 12–15/group). The data are 
presented as mean + SEM. Graph bars that do not share a letter are statistically significant different at p < 0.05.
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the mice with 4T1 tumors relative to the 67NR tumors (Fig. 6B, p < 0.001, unpaired t-test) in this study; how-
ever, as reported for cohort one, mice with 4T1 tumors had significantly greater spleen mass (Fig. 6C, p < 0.05, 
Dunn’s multiple comparisons) and hippocampal IL-1β concentration (Fig. 6D, p < 0.05, Dunn’s multiple compar-
isons) than mice with 67NR tumors. There were no significant group differences in hippocampal concentration 
of IL-6 (Fig. 6E, F2,41, p > 0.005), TNFα (Fig. 6F, F2,39, p > 0.005) IFNγ (data not shown, F2,40 = 0.9132, p > 0.005), 
IL-10 (data not shown, F2,41 = 3.207, p > 0.005), CXCL1 (data not shown, F2,41 = 0.1753, p > 0.005), IL-4 (data 
not shown, F2,40 = 0.1969, p > 0.005), IL-5 (data not shown, F2,40 = 1.887, p > 0.005), IL-2 (data not shown, 
F2,39 = 0.08792, p > 0.005), or IL-12p70 (data not shown, F2,41 = 1.109, p > 0.005). Despite group differences in 
proinflammatory cytokine concentrations, there were no group differences in the number of doublecortin (DCX) 
positive cells (Fig. 7C, F2,41 = 0.3946, p > 0.05) or in the acquisition (Fig. 7D, F2,42 = 0.1625, p > 0.05), context 
(Fig. 7E, F2,42 = 0.7435, p > 0.05), or retention (Fig. 7F, F2,42 = 0.6356, p > 0.05) phases of fear conditioning.
Discussion
This study establishes that despite similar tumor sizes there is significant variation among tumor cell lines 
in their ability to induce a peripheral and central immune response. Additionally, despite the acute cen-
tral pro-inflammatory cytokine production in the 4T07 and 4T1 tumors there were no significant changes in 
DCX + cells, affective behavior, or learned fear. Tumors generated via all three cell lines had detectable concen-
trations of IL-1β, IL-6, TNFα, CXCL1 IFN-γ, IL-2, IL-4, IL-5, IL-10, and IL-12p70 (Fig. 1C). However, tumors 
generated with 4T07 or 4T1 cells had significantly greater IL-1β, IL-6, and TNFα concentrations when compared 
to tumors generated with 67NR cells (Fig. 1C). Additionally, mice with 4T07 or 4T1 tumors had increased IL-1β, 
IL-6, TNFα, IFNγ, IL-2, IL-10, IL-4, and IL-5 in the serum along with increased concentrations of IL-1β, IL-6, 
and TNFα in the liver relative to vehicles (Figs 2 and 3). A recent paper by Masri and colleagues21 reported that 
lung adenocarcinoma can alter liver metabolism, and this shift involves the STAT3-Socs3 inflammatory signal-
ing axis. Considering mice injected with either 4T07 or 4T1 cells displayed increased IL-6 production and that 
IL-6 signals through the STAT3-Socs3 pathway; we examined mRNA expression of both liver STAT3 and Socs3. 
Indeed, 4T07 and 4T1 tumors resulted in increased STAT3 and Socs3 mRNA expression. Future studies should 
examine whether the association between liver inflammation and metabolism is specific to lung adenocarcinoma 
or exists in other types of cancer, such as breast cancer.
Importantly, tumors generated with 4T07 and 4T1 cells, but not 67NR cells, induced central pro-inflammatory 
cytokine production in both the hippocampus and cortex; specifically, there was a significant increase in the con-
centration of IL-1β for both 4T07 and 4T1 tumor bearing mice (Figs 4 and 6). Of note, there was no correlation 
between tumor or serum cytokine concentrations and concentrations of these cytokines in the brain, demon-
strating that serum cytokine concentrations do not serve as an indicator of central pro-inflammatory cytokine 
production.
Figure 3. 4T07 and 4T1 Tumors Increase Liver Inflammation and Downstream IL-6 Signaling. (A–D) Liver 
cytokine mRNA expression of IL-1β, IL-6, TNFα, and IFNγ expressed as fold change from vehicle.(A–C) 
Liver IL-1β, IL-6, and TNFα were significantly increased in 4T07 and 4T1 tumors relative to 67NR tumors 
and vehicles. (D) There were no significant differences in liver IFNγ. (E–F) mRNA levels of downstream IL-6 
signaling molecules, STAT3 and SOCS3 expressed as fold change from vehicle. (E) STAT3 mRNA expression 
was increased in 4T1 tumors relative to vehicles. (F) Liver Socs3 mRNA was significantly higher in 4T07 and 
4T1 tumors relative to 67NR tumors and vehicles. The measures and tissues were collected 20 days after tumor 
cell or vehicle inoculation (n = 12–15/group). The data are presented as mean + SEM. Graph bars that do not 
share a letter are statistically significant different at p < 0.05.
www.nature.com/scientificreports/
6ScieNTific REPORTS | 7: 8152  | DOI:10.1038/s41598-017-07596-9
To determine whether the increases in these cytokines were functionally significant, mice underwent a series 
of behavioral tests. Previous studies examining the effects of increased IL-1β and TNFα in the brain have con-
cluded that both are associated with increased depressive-like behavior and cognitive deficits22–25. However, in 
the current study, acute central pro-inflammatory cytokine production among the 4T07 and 4T1 tumor bearing 
mice was not associated with changes in depressive-like behavior. Mice displayed no changes in the number of 
floating bouts, total time floating, or latency to float during the forced swim test or the number of immobile bouts, 
time spent immobile, and latency to immobility during tail suspension test, both of which are well-characterized 
behavioral tests for depressive-like behavior (Fig. 5).
Cognitive dysfunction is another common complaint among breast cancer survivors. Tumor induced central 
pro-inflammatory cytokine production provides a potential mechanism through which cancer may impair cog-
nition. Indeed, it is well documented that central pro-inflammatory cytokine production can alter neurogenesis 
through actions on neurotrophins, particularly decreases in concentrations of brain-derived neurotrophic factor 
(BDNF), and that reductions in neurogenesis have been associated with impaired cognitive performance10, 26–29. 
With this in mind, we examined DCX + cells (an approximate measure of neurogenesis) in the hippocampus 
along with mouse performance on fear conditioning, which is a test for learned fear that includes some cogni-
tive performance measures which are dependent on the hippocampus and altered by central pro-inflammatory 
cytokine production30–33. In the current study, however, tumor-induced acute central pro-inflammatory cytokine 
production had no effect on fear conditioning performance. All groups were able to acquire the task (Fig. 7D), 
Figure 4. 4T07 and 4T1 Cell Lines Induce Central Pro-inflammatory Cytokine Production. (A–D) Cortex 
protein cytokine concentrations of IL-1β, IL-6, TNFα, and CXCL1 expressed in both vehicle and treatment 
groups. (A) Cortex IL-1β was significantly increased in 4T07 and 4T1 tumors relative to 67NR tumors and 
vehicles. (B) There were no significant differences in cortex IL-6 (C) Cortex TNFα was significantly increased 
in 4T1 tumors relative to 67NR tumors. (D) Cortex CXCL1 was significantly increased in 4T07 and 4T1 tumors 
relative to 67nR tumors and vehicles. (E–H) Hippocampus protein cytokine concentrations of IL-1β, IL-6, 
TNFα, and CXCL1 expressed in both vehicle and treatment groups. (E) Hippocampus IL-1β was significantly 
increased in 4T07 and 4T1 tumors relative to 67NR tumors and vehicles. (F) There were no significant 
differences in hippocampal IL-6. (G) Hippocampal TNFα was significantly increased in 4T07 tumors relative 
to vehicles. (H) There were no significant differences in hippocampal CXCL1. (I–L) mRNA levels expressed as 
fold change from vehicles for IDO1 (enzyme implicated in etiology of depression), IDO2 (enzyme implicated 
in etiology of depression), BNDF (neurotrophin), and PSD-95 (marker of postsynaptic densities); There were 
no significant differences in mRNA expression of IDO1, IDO2, BDNF, or PSD-95. The measures and tissues 
were collected 20 days after tumor cell or vehicle inoculation (n = 12–15/group). The data are presented as 
mean + SEM. Graph bars that do not share a letter are statistically significant different at p < 0.05.
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and there were no differences in either the context or retention phases of fear conditioning (Fig. 7E,F). Consistent 
with the behavioral data, there was an absence of a tumor effect on BDNF gene expression and DCX + cells 
(approximate measure of neurogenesis; Figs 4J and 7C). DCX staining was used in this study instead of the more 
specific BrdU/DCX/NeuN co-staining because it did not require daily handling and injection and eliminated 
possible contamination of the behavioral equipment through excreted BrdU.
Although two of the cell lines used in the current study resulted in acute central pro-inflammatory cytokine 
production, the affective and cognitive deficits reported previously to be associated with tumor-induced cytokine 
production were not apparent in the 4T1 tumor bearing mice. There are several experimental differences between 
the current study and previous studies that may have contributed to this discrepancy in affective and cognitive 
outcomes. Importantly, previous studies have used either carcinogens or nonorthotopic tumor models to examine 
the effects of tumor-induced central pro-inflammatory cytokine production on behavior11–14, 34, 35. Additionally, 
previous studies have differed in species tested11, 34,number of cells injected to initiate the tumor, size of tumors, 
and timing of tissue collection12–14, 35.
Clinical studies have demonstrated an increased incidence of depression and cognitive deficits in cancer 
patients prior to any treatment36, 37. Of note, incidence rates of depression and cognitive deficits increase during 
cancer treatment1, 37. However, this study sought to examine the behavioral effects of peripheral tumors prior to 
any medical intervention. In the current study, sizeable mammary tumors did not induce behavioral deficits in 
Balb/C mice within our timeline. Time is a limiting factor in these studies due to the exponential growth pattern 
of the tumors. Indeed, the potential for confounding effects of tumor size on behavior increases as the tumors 
grow and alter locomotor activity. For the current study, a time point was chosen for behavioral testing that coin-
cided with increased CNS cytokine expression in prior tumor cell line studies13, 38 but prior to the onset of loco-
motor deficits. Although there are examples of behavior deficits emerging within hours of increased CNS cytokine 
expression39, 40, it is possible that longer-term exposure to increased tumor-associated pro-inflammatory cytokine 
concentrations would have led to behavioral deficits. Future studies conducting a time course with slower grow-
ing tumors may be able to address this question. Interestingly, cognitive and affective disorders also can emerge 
in response to tumor induced sleep disruption; sleep disturbances are reported in 30–50% of cancer patients41. 
Central pro-inflammatory cytokine production can contribute to sleep alterations that persist over time, in turn 
eliciting affective changes and cognitive deficits42–45. Future directions should compare these cells lines’ effects on 
sleep. If reproduced in mouse models of cancer, then sleep deficits could have the potential to serve as predictors 
of future behavioral deficits, ultimately allowing for earlier interventions and prevention.
Figure 5. Locomotor Deficits or Depressive-like Behaviors are not Induced by Mammary Tumors. (A) Total 
number of beam breaks for vehicle and treatment groups during open field testing. There were no significant 
differences in total locomotor activity. (B) Immobility time during tail suspension test for vehicle and treatment 
groups. There were no significant differences in time spent immobile. (C–D) Average time spent floating and 
number of floating bouts for vehicle and treatment groups during forced swim test. There were no significant 
differences in floating duration or floating bouts. The measures and tissues were collected 20 days after tumor 
cell or vehicle inoculation (n = 12–15/group). The data are presented as mean + SEM. Graph bars that do not 
share a letter are statistically significant different at p < 0.05.
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The mice in the current study were individually housed because social interactions can influence tumor 
growth46, 47 and CNS cytokine expression48, 49, which in turn would make data collected from the two animals 
within the cage non-independent. Although individual housing may have affected baseline behavior50, the 
approach is well-founded given that socially isolated cancer patients are more susceptible to affective disorders51, 52. 
Furthermore, social isolation typically amplifies CNS cytokine expression in the context of an inflammatory stim-
ulus and the associated behaviors49. Regardless, the role of social interactions in the development of physiological 
and behavioral sequelae of cancer is an intriguing question that warrants examination.
The current study provides several examples of cell-line specific physiological changes despite similarly sized 
tumors, but the underlying causes remain unknown. Interestingly, the two cell lines that were associated with 
increased serum, liver, and brain inflammation in the current study have the ability to undergo epithelial to 
mesenchymal transition and leave the primary site (4T07 and 4T1), whereas the non-metastatic cell line (67NR) 
was not associated with increased cytokine concentrations in serum, liver or brain. Indeed, 4T1 tumors may 
result in lung and lymph node micro-metastasis as early as 14 days post-injection53, but this is unlikely to be the 
full explanation because there were very few significant differences in inflammatory outcome measures between 
the 4T1 and 4T07 groups even though the 4T07 group would not be expected to have metastases20. Additional 
studies are needed to determine the specific characteristics of these mammary tumors that are responsible for the 
exaggerated proinflammatory response observed in multiple organ systems.
In sum, 4T07 and 4T1 mammary tumors have the ability to induce peripheral and central immune responses. 
However, despite the acute central pro-inflammatory cytokine production produced by the 4T07 and 4T1 tumors, 
there were no significant changes in DCX + cells (an approximate measure of neurogenesis), affective behavior, 
or learned fear relative to vehicle treated control mice and those with 67NR tumors. These data demonstrate that 
the physiological and behavioral effects of mammary tumors are cell-line specific and that short-term central 
pro-inflammatory cytokine production does not produce behavioral deficits. Furthermore, these data imply that 
the cause of cognitive and affective changes among breast cancer survivors are more likely due to the effects of 
cancer treatments, than the tumor, on brain tissue. Further study of the independent and interactive effects of 
tumors and pharmacological treatments for cancer on the brain are warranted.
Methods
Animals. Adult (>7 weeks) female Balb/C mice were obtained from Charles River Laboratories. Mice were 
individually housed and allowed ad libitum access to food and filtered tap water throughout the course of the 
Figure 6. 4T1 Cells Generate both a Peripheral and Central Response. (A) Body mass difference between day of 
tumor inoculation (DOI) and day of euthanasia (DOE) accounting for tumor mass (TTB) for vehicle and each 
cell line ((DOE-DOI)-TTB). 4T1 tumors had reduced weight gain relative to vehicles. (B) Total tumor burden in 
grams; 4T1 tumors had significantly increased mass. (C) Spleen mass for vehicle and treatment groups. Spleen 
mass was significantly increased in 4T1 tumors relative to 67NR tumors and vehicles. (D–F) Hippocampus 
protein cytokine concentrations of IL-1β, IL-6, and TNFα expressed in both vehicle and treatment groups. (D) 
Hippocampal IL-1β was significantly increased in 4T1 tumors relative to 67NR tumors and vehicles. (E) There 
were no significant differences in hippocampal IL-6. (F) TNFα was increased in the hippocampus of 4T1 treated 
mice relative to vehicles. The measures and tissues were collected 20 days after tumor cell or vehicle inoculation 
(n = 12–15/group). The data are presented as mean + SEM. Graph bars that do not share a letter are statistically 
significant different at p < 0.05.
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experiment. Cohort one consisted of 60 mice which were randomly assigned groups consisting of the vehicle 
(DMEM) control treatment or tumors generated using one of three tumor cell lines (n = 15 vehicle, n = 15 67NR, 
n = 15 4T07, n = 15 4T1). The mice received 100 μl orthotopic bilateral injections of either tumor cells (1 × 105 
per injection; cell lines described in detail below) or vehicle (DMEM) into the fourth and ninth inguinal mam-
mary glands. On the morning of Day 20 following tumor inoculations, mice underwent behavioral testing which 
consisted of open field (assesses locomotor behavior and anxiety-like behavior), tail suspension (assesses depres-
sive-like behavior), and forced swim testing (assesses depressive-like behavior). Approximately 4 h after testing, 
body mass was recorded, a blood sample was collected from the submandibular vein, and then the mouse was 
euthanized for tissue collection; spleen, liver, and tumors were dissected and placed in sterile tubes containing 
RNA later (Invitrogen, Waltham, MA). The brains were dissected into the left and right hemispheres and placed in 
tubes containing RNA later (Invitrogen, Waltham, MA) and stored at −80 °C; two days later, the cortex and hip-
pocampus were dissected from both hemispheres, one hemisphere for processing for PCR (gene expression) and 
the other hemisphere for analysis of protein cytokine levels via multiplex assay. To determine whether any groups 
experienced significant weight loss, body mass measurements were obtained for each mouse and subtracted from 
individual body mass on the day of injection. Next, total tumor burden was subtracted from this difference to 
account for the mass of the tumor ((Body Mass Day of Euthanasia- Body Mass Day of Injection)- Total Tumor 
Burden). Cohort two consisted of 45 mice (n = 15 vehicle, n = 15 67NR, and n = 15 4T1) that were randomly 
assigned to experimental groups. All mice received 100 μl orthotopic bilateral injections of either tumor cells 
(67NR or 4T1, 1 × 105 per injection) or vehicle (DMEM) into to the fourth and ninth inguinal mammary glands. 
Mice underwent learned fear assessment via fear conditioning; the acquisition training occurred during the 
light period of Day 18 after tumor induction and then context training (light period) and retention testing (dark 
period) occurred the following day. On Day 20, body mass was recorded, a blood sample was collected from the 
submandibular vein, and then the mouse was euthanized for tissue collection; spleen, liver, and tumors were dis-
sected and placed in sterile tubes containing RNA later (Invitrogen, Waltham, MA). The brains were split into the 
left and right hemispheres; one hemisphere was placed in RNA later (Invitrogen, Waltham, MA) and processed 
for the multiplex assay as described above, while the other hemisphere was post-fixed in 4% paraformaldehyde 
overnight, and then transferred to a 30% sucrose solution. After cryoprotection, brains were frozen at −80o C 
until sectioning. All experiments were approved and carried out in accordance with guidelines set by The Ohio 
State University Institutional Animal Care and Use Committee.
Cell Lines and Orthotopic Injections. 67NR, 4T07, and 4T1 cells were obtained from Barbara Ann 
Karmanos Cancer Institute (Detroit, MI). These cell lines are distinct isolated subpopulations from a single 
spontaneous Balb/cfC3H mammary tumor, and differ in their ability to induce secondary metastasis. 67NR cells 
fail to leave the primary site, while 4T07 cells have the ability to leave the primary site but fail to complete the 
Figure 7. Learned Fear and Neurogenesis are not Altered by Mammary Tumors. (A,B) Representative IHC 
Staining of neurogenesis in the dentate gyrus of the hippocampus vehicle and 4T1 treatment groups (DCX in 
red and DAPI in blue). (C) Mean number of DCX + cells in the subgranular zone of the dentate gyrus. There 
were no significant differences in the number of DCX + cells. (D–F) Acquisition, context, and retention phases 
of fear conditioning testing. There were no significant differences in acquisition, context, and retention during 
fear conditioning. The measures and tissues were collected 18–20 days after tumor cell or vehicle inoculation 
(n = 12–15/group). The data are presented as mean + SEM. Graph bars that do not share a letter are statistically 
significant different at p < 0.05.
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metastatic cascade and form visible metastases. However, 4T1 cells both leave the primary site and form visi-
ble secondary metastases20. Cells were cultured in high glucose Dulbecco’s Modified Eagle Medium (DMEM) 
with L-glutamine (Gibco11965) supplemented with 10% certified heat inactivated fetal bovine serum (Gibco 
10082), 1% antibiotic-antimycotic (Gibco 15240), and 0.12% mixed nonessential amino acids (Gibco 11140). 
Cells were maintained in an incubator at 37 °C with a mixture of 5% carbon dioxide and 95% air. Prior to injec-
tions cells underwent mycoplasma testing using the PlasmoTest kit (InvivoGen, San Diego, CA) and were verified 
to be free of any mycoplasma contamination. Cell passage numbers were the same throughout the experiment. 
Cells were diluted in a 1:1 mixture of trypan blue (Life Technologies, Carlsbad, CA) and were counted using an 
automated cell counter (Cell Countess II, Life Technologies, Carlsbad, CA). For injections cells were diluted in 
DMEM (Gibco 11965) for a concentration of 1 × 105 per 100 μl. Mice were briefly anesthetized using isoflurane 
and a small 2–3 mm midline incision was made directly between the fourth and ninth inguinal mammary glands, 
allowing visualization of both glands. Each mammary gland was injected with 100 μl of either tumor cells (1 × 105 
cells) or vehicle (DMEM). As tumors became palpable, measurements were obtained every three days using slid-
ing calipers; tumor volume was calculated using the following formula: tumor volume = (length × width2)/254. 
Mice displaying skin ulceration or tumor size meeting the endpoint criteria (1.5 cm in any direction) prior to 
conclusion of the study were euthanized immediately and not included in data analyses (n = 4 in cohort 1).
RNA Extraction, cDNA, and PCR. RNA was extracted using Trizol Reagent (Ambion, Waltham, MA) 
according to the manufacturer’s instructions. RNA quantity and quality was determined using a spectrophotom-
eter (Nanodrop One, Wilmington, DE). cDNA was synthesized using M-MLV reverse transcriptase and diluted 
1:10 for subsequent PCR. Inventoried probes from Applied Biosystems (Life Technologies, Carlsbad, CA) were 
used (Table 1). Taqman Fast Advanced Master Mix (Life Technologies, Carlsbad, CA) containing AmpliTaq Fast 
DNA Polymerase were used in a 20 μL duplex reaction with one probe (Table 1) and a primer-limited probe for 
the endogenous eukaryotic control 18 s rRNA. The 2-step real-time PCR cycling conditions used were 95 °C for 
20 s, 40 cycles of 95 °C for 3 s, and then 60 °C for 30 s. Gene expression was quantified using the Pfaffl Method55.
Protein Multiplex. Prior to running the multiplex, extracted hippocampi, cortex, and tumors were first 
sonicated in RIPA buffer and allowed to sit on ice for 30 min. Following 30 min incubation samples were then 
centrifuged at 13,300 rpm for 15 min at 4 °C and supernatant was taken. Pierce BCA Protein Assay Kit was then 
run to insure equal amount of protein was loaded into multiplex. To determine cytokine protein levels serum, 
tumor, cortex, and hippocampus samples were analyzed using Meso Scale Discover V-Plex Pro-inflammatory 
Mouse Panel according to manufacturer’s instructions. The kit measures protein levels of the following cytokine 
and chemokines: IFNγ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-5, IL-6, KC/Gro (CXCL1), and TNFα. The plates 
were run on a Meso Quickplex machine and the data analyzed using MSD Discovery Workbench software v4.0.
DCX Staining and Quantification. The paraformaldehyde and sucrose treated brains from Cohort 2 were 
sectioned at 30 μm into four series using a cryostat. Only series one was used for the doublecortin (DCX) stain-
ing. Free-floating brain sections were washed three times with PBS (pH 7.4; 5 min each), and then treated with 
Tris-EDTA (pH 8.0; 10 min) for antigen retrieval. After three additional washes with PBS (5 min each), sections 
were treated with 2.5% normal horse serum dissolved in 10 mM PBS containing 0.1% Triton-X-100 (PBSHT) 
for 45 min to block non-specific binding. Next, sections were incubated with a goat polyclonal anti-DCX anti-
body (dilution 1:200; sc-8066; Santa Cruz Biotechnology) in PBSHT overnight at room temperature. Thereafter, 
sections were washed three times in PBS (5 min each) and incubated with the donkey anti-goat immunoglob-
ulin G conjugated to Alexa Fluor 594 (dilution 1:200; A11058; Invitrogen) in PBSHT for 2 h at room temper-
ature. Finally, sections were washed three times in PBS for 5 min each, mounted onto glass slides, treated with 
Vectashield mounting medium with DAPI (H-1500; Vector Laboratories Inc.), coverslipped and visualized in the 
Cy3 channel (Zeiss AxioImager M2). All images of the subgranular zone of the dentate gyrus were taken at 20x 















Table 1. Gene names and assay ids for TaqMan primer/probe sets used throughout the experiment.
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magnification. All DCX + cells in the subgranular zone were counted by an experimenter blind to experimental 
assignments.
Behavioral Testing. Open Field Testing. Mice were placed for 10 min in a polypropylene open field arena 
(36 cm × 36 cm) with two rows of infrared sensors mounted on the sides of the box to detect movement (Open 
Field Photobeam Activity System, San Diego Instruments Inc). These boxes are contained in cabinets which allow 
for experimenter manipulation of lights and attenuation of outside sound. For each mouse total activity (i.e. beam 
breaks) and central tendency was calculated and analyzed.
Forced Swim Test. Mice were placed for 5 min in a 5000 ml beaker filled with 3500 ml of water at ~27 °C. Mice 
were videotaped and their behavior was later scored using The Observer XT 8.0 software (Noldus, Leesburg, VA). 
Latency to float, time spent floating, and number of floating bouts were calculated and analyzed for each mouse.
Tail Suspension Test. Mice were suspended for 5 min by their tail, which was taped to the top edge of a 92 cm 
high box. Mice were videotaped and their behavior was later scored by hand using The Observer XT 8.0 software 
(Noldus, Leesburg, VA). Time spent immobile was calculated and analyzed for each mouse.
Fear Conditioning. This test is comprised of three testing sessions (acquisition, context, retention) over two days. 
The testing apparatus (MedAssociates, St. Albans, VT) consists of a Plexiglas box which contains a metal floor 
through which a shock is administered. The entire Plexiglas box is housed inside a cabinet that blocks out both 
external light and sound. A video camera is mounted on the door of the chamber and records the movement and 
freezing of each mouse. Time spent freezing for each mouse was calculated and analyzed using VideoFreeze soft-
ware (MedAssociates, St. Albans, VT). Acquisition trial (Day 18) consisted first of a 180 sec acclimation period, 
followed by an 80 dB tone for 20 sec and a 0.6 mA shock during the last second of the tone. This 20 sec tone and 
shock pairing was administered seven times with a 30 sec inter-trial interval. This trail concluded with a 60 sec-
ond observation period. Following the trial mice were placed back in their home cage. The context trial (Day 
19 morning) consisted of each mouse being placed in the Plexiglas box for 180 seconds with no tone or shock 
administered. Behavior was recorded and following completion of the trail the mice were returned to their home 
cages. The retention trial consisted first of changing the environment to make it less recognizable for the mice. 
White inserts were used both to cover the metal grid floor and change the shape of the box to semi-circular. 
Vanilla extract was placed in the bottom of the box to change the odor. The trial design was exactly the same as 
the acquisition trail except no shock was administered. Following completion of the trial, mice were returned to 
their home cages.
Statistical Analysis. Outliers were identified and subsequently removed prior to analyses using the Grubb’s 
Test. All data except for retention and acquisition stages of fear conditioning were analyzed using a one-way 
ANOVA. Post-hoc analyses were performed using Tukey’s multiple comparisons test. If data did not meet the 
assumptions of ANOVA, then statistical analyses were conducted using a nonparametric Kruskal-Wallis test. 
Post-hoc analyses on nonparametric data were performed using Dunn’s multiple comparisons test. For both the 
acquisition and retention stages of fear conditioning two-way repeated measures ANOVA was used for subse-
quent analyses. Post-hoc analyses were performed using Tukey’s multiple comparisons test. Correlations were 
assessed using Pearson’s correlations. P < 0.05 was considered significant for all data except those acquired using 
the Meso Scale Discover V-Plex Pro-inflammatory Mouse Panel. To account for the simultaneous measurement 
of 10 analytes in the same sample p < 0.005 was considered significant (0.05/10 = 0.005). All statistical analyses 
were performed using GraphPad Prism 6.0 software.
Data Availability. The data that support the findings of this study are available (in raw form) from the corre-
sponding author upon reasonable request.
References
 1. Reich, M., Lesur, A. & Perdrizet-Chevallier, C. Depression, quality of life and breast cancer: a review of the literature. Breast Cancer 
Res. Treat. 110, 9–17 (2008).
 2. McDaniel, J. S., Musselman, D. L., Porter, M. R., Reed, D. A. & Nemeroff, C. B. Depression in Patients With Cancer. Arch. Gen. 
Psychiatry 52, 89 (1995).
 3. DiMatteo, M. R. et al. Correspondence Among Patients’ Self-Reports, Chart Records, and Audio/Videotapes of Medical Visits. 
Health Commun. 15, 393–413 (2003).
 4. Spiegel, D. & Giese-Davis, J. Depression and cancer: mechanisms and disease progression. Biol. Psychiatry 54, 269–282 (2003).
 5. Wong-Kim, E. C. & Bloom, J. R. Depression experienced by young women newly diagnosed with breast cancer. Psychooncology. 14, 
564–573 (2005).
 6. Bower, J. E. Behavioral symptoms in patients with breast cancer and survivors. J. Clin. Oncol. 26, 768–77 (2008).
 7. Fann, J. R. et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen. Hosp. Psychiatry 30, 112–126 
(2008).
 8. Sotelo, J. L., Musselman, D. & Nemeroff, C. The biology of depression in cancer and the relationship between depression and cancer 
progression. Int. Rev. Psychiatry 26, 16–30 (2014).
 9. Prasad, S. M. et al. Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J. Clin. 
Oncol. 32, 2471–8 (2014).
 10. Maes, M. et al. The inflammatory &amp; neurodegenerative (I&amp;ND) hypothesis of depression: leads for future research and 
new drug developments in depression. Metab. Brain Dis. 24, 27–53 (2009).
 11. Pyter, L. M., Pineros, V., Galang, J. A., McClintock, M. K. & Prendergast, B. J. Peripheral tumors induce depressive-like behaviors 
and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc. Natl. Acad. Sci. USA. 106, 9069–9074 
(2009).
www.nature.com/scientificreports/
1 2ScieNTific REPORTS | 7: 8152  | DOI:10.1038/s41598-017-07596-9
 12. Lamkin, D. M. et al. Cancer induces inflammation and depressive-like behavior in the mouse: Modulation by social housing. Brain. 
Behav. Immun. 25, 555–564 (2011).
 13. Yang, M. et al. Hippocampal dysfunctions in tumor-bearing mice. Brain. Behav. Immun. 36, 147–155 (2014).
 14. Norden, D. M. et al. Tumor growth increases neuroinflammation, fatigue and depressive-like behavior prior to alterations in muscle 
function. Brain. Behav. Immun. 43, 76–85 (2015).
 15. Nicolini, A., Carpi, A. & Rossi, G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 17, 325–337 (2006).
 16. Dantzer, R., Konsman, J.-P., Bluthé, R.-M. & Kelley, K. W. Neural and humoral pathways of communication from the immune 
system to the brain: parallel or convergent? Auton. Neurosci. 85, 60–65 (2000).
 17. Maier, S. F. & Watkins, L. R. Immune-to-central nervous system communication and its role in modulating pain and cognition: 
Implications for cancer and cancer treatment. Brain. Behav. Immun. 17, 125–131 (2003).
 18. Dantzer, R., OConnor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the 
immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–56 (2008).
 19. Quan, N. Immune-To-Brain Signaling: How Important are the Blood–Brain Barrier-independent Pathways? Mol. Neurobiol. 37, 
142–152 (2008).
 20. Heppner, G. H., Miller, F. R. & Shekhar, P. M. Nontransgenic models of breast cancer. Breast Cancer Res. 2, 331–334 (2000).
 21. Masri, S. et al. Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis. Cell 165, 896–909 (2016).
 22. Tanaka, S. et al. Lipopolysaccharide-induced microglial activation induces learning and memory deficits without neuronal cell 
deathin rats. J. Neurosci. Res. 83, 557–566 (2006).
 23. Goshen, I. et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and 
hippocampal neurogenesis suppression. Mol. Psychiatry 13, 717–728 (2008).
 24. Karson, A., Demirtaş, T., Bayramgürler, D., Balcı, F. & Utkan, T. Chronic Administration of Infliximab (TNF-α Inhibitor) Decreases 
Depression and Anxiety-like Behaviour in Rat Model of Chronic Mild Stress. Basic Clin. Pharmacol. Toxicol. 112, 335–340 (2013).
 25. Belarbi, K. et al. TNF-a protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic 
neuroinf lammation. athttp://download.springer.com/static/pdf/670/art%253A10.1186%252F1742-2094-9-23.
pdf?originUrl=http%3A%2F%2Fjneuroinflammation.biomedcentral.com%2Farticle%2F10.1186%2F1742-2094-9-23&token2=ex
p= 1 4 9 1 4 3 0 9 1 5 ~ a c l=% 2 F s t a t i c % 2 F p d f % 2 F 6 7 0 % 2 F a r t % 2 5 2 5 3 A 1 0 . 1 1 8 6 % 2 5 2 5 2 F 1 7 4 2 - 2 0 9 4 - 9 - 2 3 .
pdf*~hmac=742ed80c52f5303faea6fc4e55d7c3be83b3b98ba825dd69777f9265054c616f.
 26. Ekdahl, C. T., Claasen, J.-H., Bonde, S., Kokaia, Z. & Lindvall, O. Inflammation is detrimental for neurogenesis in adult brain. Proc. 
Natl. Acad. Sci. USA. 100, 13632–7 (2003).
 27. Graciarena, M., Depino, A. M. & Pitossi, F. J. Prenatal inflammation impairs adult neurogenesis and memory related behavior 
through persistent hippocampal TGFβ1 downregulation. Brain. Behav. Immun. 24, 1301–1309 (2010).
 28. Kohman, R. A. & Rhodes, J. S. Neurogenesis, inflammation and behavior. Brain. Behav. Immun. 27, 22–32 (2013).
 29. Apple, D. M., Fonseca, R. S. & Kokovay, E. The role of adult neurogenesis in psychiatric and cognitive disorders. Brain Res. 1655, 
270–276 (2017).
 30. Phillips, R. G. & LeDoux, J. E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. 
Behav. Neurosci. 106, 274–285 (1992).
 31. Saxe, M. D. et al. Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate 
gyrus. Proc. Natl. Acad. Sci. USA. 103, 17501–6 (2006).
 32. Burton, M. D. Interleukin-6 trans-signaling in the senescent mouse brain is involved in infection-related deficits in contextual fear 
conditioning. Brain. Behav. Immun. 26, 732–738 (2012).
 33. Terrando, N. et al. The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Crit. 
Care 14 (2010).
 34. Pyter, L. M. et al. Mammary tumors induce select cognitive impairments. Brain. Behav. Immun. 24, 903–7 (2010).
 35. Lebeña, A. et al. Melanoma tumors alter proinflammatory cytokine production and monoamine brain function, and induce 
depressive-like behavior in male mice. Behav. Brain Res. 272, 83–92 (2014).
 36. Hegel, M. T. et al. Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer. 
Cancer 107, 2924–2931 (2006).
 37. Janelsins, M. C., Kesler, S. R., Ahles, T. a. & Morrow, G. R. Prevalence, mechanisms, and management of cancer-related cognitive 
impairment. Int. Rev. Psychiatry 26 (2014).
 38. Norden, D. M. et al. Ibuprofen ameliorates fatigue- and depressive-like behavior in tumor-bearing mice. Life Sci. 143, 65–70 (2015).
 39. Lee, J. et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid 
generation. J. Neuroinflammation 5, 37 (2008).
 40. Godbout, J. P. Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune 
system. FASEB J. 19, 1329–1331 (2005).
 41. Davidson, J. R., MacLean, A. W., Brundage, M. D. & Schulze, K. Sleep disturbance in cancer patients. Soc. Sci. Med. 54, 1309–1321 
(2002).
 42. Krueger, J. M., Obál, F., Fang, J., Kubota, T. & Taishi, P. The Role of Cytokines in Physiological Sleep Regulation. Ann. N. Y. Acad. Sci. 
933, 211–221 (2006).
 43. Imeri, L. & Opp, M. R. How (and why) the immune system makes us sleep. Nat. Rev. Neurosci. 10, 199–210 (2009).
 44. Benca, R. M., Obermeyer, W. H., Thisted, R. A. & Gillin, J. C. Sleep and Psychiatric Disorders. Arch. Gen. Psychiatry 49, 651 (1992).
 45. Walker, M. P. Cognitive consequences of sleep and sleep loss. Sleep Med. 9, S29–S34 (2008).
 46. Strange, K. S., Kerr, L. R., Andrews, H. N., Emerman, J. T. & Weinberg, J. Psychosocial stressors and mammary tumor growth. 
Neurotoxicol. Teratol. 22, 89–102 (2000).
 47. Stefanski, V. & Ben-Eliyahu, S. Social confrontation and tumor metastasis in rats: Defeat and-adrenergic mechanisms. Physiol. 
Behav. 60, 277–282 (1996).
 48. Audet, M. C., Jacobson-Pick, S., Wann, B. P. & Anisman, H. Social defeat promotes specific cytokine variations within the prefrontal 
cortex upon subsequent aggressive or endotoxin challenges. Brain. Behav. Immun. 25, 1197–1205 (2011).
 49. Norman, G. J. et al. Social interaction prevents the development of depressive-like behavior post nerve injury in mice: a potential 
role for oxytocin. Psychosom. Med. 72, 519–526 (2010).
 50. Brenes, J. C., Rodríguez, O. & Fornaguera, J. Differential effect of environment enrichment and social isolation on depressive-like 
behavior, spontaneous activity and serotonin and norepinephrine concentration in prefrontal cortex and ventral striatum. 
Pharmacol. Biochem. Behav. 89, 85–93 (2008).
 51. Hann, D. M., Oxman, T. E., Ahles, T. A., Furstenberg, C. T. & Stuke, T. A. Social support adequacy and depression in older patients 
with metastatic cancer. Psychooncology. 4, 213–221 (1995).
 52. Breitbart, W. Identifying patients at risk for, and treatment of major psychiatric complications of cancer. Support. Care Cancer 3, 
45–60 (1995).
 53. Pulaski, B. A. & Ostrand-Rosenberg, S. Reduction of Established Spontaneous Mammary Carcinoma Metastases following 
Immunotherapy with Major Histocompatibility Complex Class II and B7.1 Cell-based Tumor Vaccines. Cancer Res. 58 (1998).
 54. Tomayko, M. M. & Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. 
Pharmacol. 24, 148–154 (1989).
 55. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, 45e–45 (2001).
www.nature.com/scientificreports/
13ScieNTific REPORTS | 7: 8152  | DOI:10.1038/s41598-017-07596-9
Acknowledgements
This research was supported by the National Cancer Institute (R01CA194024 to ACD) and the National Institute 
of Neurological Disorders and Stroke (P30NS045758). We would further like to thank the Ohio State University 
Laboratory Animal Resources for their exceptional care of the mice used in this study.
Author Contributions
W.H.W.II designed, completed, analyzed all experiments and wrote the manuscript; J.B., S., N.Z., A.A.Z., S.L.M., 
J.A.F., M.M.G.-D. conducted experiments and provided editorial comments on the paper; A.C.D. designed 
experiments and wrote and edited the manuscript.
Additional Information
Competing Interests: The authors are unaware of any conflict of interest associated with the studies presented 
in this manuscript.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
